Head-to-head comparison
Peter MD vs Youth & Soul
Two GLP-1 providers, one scorecard. Both are graded on the same six Desk Score dimensions — here is how they stack up, and which one fits you.
Desk Score
A physician-prescribed telehealth brand pairing GLP-1 tirzepatide and compounded semaglutide+B12 with TRT, sermorelin, NAD+, hair-loss and ED care on one account — tirzepatide from $249/mo, semaglutide+B12 from $149/mo.
$149/mo (first month only) sema · $249/mo (quarterly prepay) tirz · Verified August 2026
Marked down on: Tirzepatide steps up after month one — $149 for the first month, then $249/mo billed quarterly
Desk Score
Ten-vertical telehealth marketplace selling compounded GLP-1 tiers alongside HRT, ED, nootropics and peptides, running on the Bask Health platform.
From $149/mo (lowest dose rung) sema · $399/mo tirz · Verified July 2026
Marked down on: Describes its compounded medications as FDA-Approved Compounds, which is false: compounded drugs are not FDA-approved
Peter MD takes this head-to-head with the higher Desk Score, 77/100 (C+) against 55/100 (C) for Youth & Soul. Youth & Soul still holds its ground where its strengths line up with yours.
Desk Score, dimension by dimension
Same six measured dimensions for both. The red flag marks the stronger side. See the methodology.
Peter MD
77/100
C+
Youth & Soul
55/100
C
Price transparency
State access
Molecule range
Onboarding speed
Support responsiveness
Licensing & trust
The spec sheet
| Field | Peter MD | Youth & Soul |
|---|---|---|
| Semaglutide | $149/mofirst month only$149/mo (GLP1+B12, compounded, first-time tier; $139/mo returning-patient tier) | From $149/molowest dose rung$149/mo (starting dose, compounded) |
| Tirzepatide | $249/moquarterly prepay$249/mo (60mg, billed quarterly; $149 first month) | $399/mo$399/mo (compounded) |
| Coverage | Most states (restrictions vary by treatment — excludes several, incl. AL, ID) | Not listed on Youth & Soul's site (checked July 2026) |
| Brand-name | Compounded only | Compounded only |
| Oral option | Injectable only | Injectable only |
| Best for | Patients who want GLP-1 care alongside TRT, NAD+, sermorelin or other men's-health treatments under one physician-guided account, and don't need brand-name or oral routes. | Shoppers who want many treatment categories in one account and are willing to verify claims themselves. |
| Desk Score | 77/100C+ | 55/100C |
The verdict
Desk pick — Peter MDPeter MD takes this head-to-head with the higher Desk Score, 77/100 (C+) against 55/100 (C) for Youth & Soul. Youth & Soul still holds its ground where its strengths line up with yours.
Choose Peter MD if…
Patients who want GLP-1 care alongside TRT, NAD+, sermorelin or other men's-health treatments under one physician-guided account, and don't need brand-name or oral routes.
$149/mo (first month only) sema · $249/mo (quarterly prepay) tirz · Most states (restrictions vary by treatment — excludes several, incl. AL, ID)
Choose Youth & Soul if…
Shoppers who want many treatment categories in one account and are willing to verify claims themselves.
From $149/mo (lowest dose rung) sema · $399/mo tirz
Assume any provider we list may compensate us — we may earn a referral commission at no extra cost to you, and what we write about a provider reads the same either way. Read full breakdowns: Peter MD · Youth & Soul.
Also here
CoreAge Rx leads the whole ranking at 94/100
Whichever of these two you lean toward, our #1-rated provider outscores them both. One price at every dose, both molecules, all 50 states. The $99 and $149 figures are 12-month plans paid up front, not a monthly bill.
More head-to-heads
- CoreAge Rx vs Peter MD
- CoreAge Rx vs Youth & Soul
- Ondra Health vs Peter MD
- Ondra Health vs Youth & Soul
- Peter MD vs Tyde Wellness
- Tyde Wellness vs Youth & Soul
Or see the full comparison hub and the complete ranking.
Pricing and verification reflect each provider's public disclosures at last scoring; the Desk Score is our editorial judgment per the methodology. Prices change — confirm on each provider's own site. Not medical advice; see our disclosure.